The Epigenetic Clock Development Foundation (EIN: 85-1457272) is dedicated to advancing medical research on aging and longevity through the development of epigenetic clocks, which serve as biomarkers for evaluating the efficacy of longevity treatments in both preclinical and clinical studies. With an operating budget of $1.8 million and total revenue of $2.1 million for the 2024 filing year, the foundation demonstrates a commitment to rigorous scientific inquiry in the field of bioethics. It does not rely on a single funder for 50% or more of its revenue and can be explored further at www.clockfoundation.org.